Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis - Scorecard - MDSpire
Advertisement
Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis
Clinical Scorecard: Comparative Analysis of Treatment Features and Safety Profiles of Belbuca®, Buprenorphine Patch, and Oral Schedule II Opioids in Chronic Low Back Pain Patients Lacking a History of Opioid Use Disorder: A Retrospective Study Using US Commercial Claims Data
At a Glance
Category
Detail
Condition
Chronic Low Back Pain (cLBP)
Key Mechanisms
Evaluation of safety characteristics of Belbuca®, buprenorphine patch, and oral schedule II opioids.
Target Population
Patients with chronic low back pain without a history of opioid use disorder.
Care Setting
Retrospective analysis using US commercial claims data.
Key Highlights
Belbuca® showed a lower rate of serious opioid abuse/dependence compared to oral CII opioids.
No serious treatment-emergent adverse events were more frequent in the Belbuca® cohort than in oral CII opioids.
The buprenorphine patch cohort had higher incidence rates of serious QT prolongation and opioid abuse/dependence.
Guideline-Based Recommendations
Diagnosis
Patients must have two low back pain diagnoses and no opioid use disorder in the preindex period.
Management
Management of cLBP depends on disease severity, with lifestyle changes and non-opioid medications recommended for low-to-moderate severity.
Monitoring & Follow-up
Continuous healthcare coverage during the observational period is required.
Risks
Opioid medications are associated with serious treatment-related adverse events, including opioid use disorder.
Patient & Prescribing Data
Commercially insured patients with chronic low back pain.
Belbuca® may have a favorable safety profile compared to oral CII opioids and buprenorphine patches.
Clinical Best Practices
Utilize buprenorphine as a safer alternative to standard opioids for chronic pain management.
Consider the unique pharmacological characteristics of buprenorphine when developing treatment plans.
A review of 56 qualitative studies found residents' emotional experiences were influenced by interactions among training demands, workplace relationships, and their evolving professional identity.
These 10 factors were identified in national surveys and peer-reviewed studies examining physician burnout, workload, administrative burden, staffing challenges, and practice conditions.
